30 results on '"Dirk Debus"'
Search Results
2. Treatment management for BRAF-mutant melanoma patients with tumor recurrence on adjuvant therapy: a multicenter study from the prospective skin cancer registry ADOREG
- Author
-
Dirk Schadendorf, Carola Berking, Jessica C Hassel, Lisa Zimmer, Ralf Gutzmer, Alexander Kreuter, Andrea Forschner, Bastian Schilling, Selma Ugurel, Katharina C Kähler, Peter Mohr, Patrick Terheyden, Felix Kiecker, Henner Stege, Sebastian Haferkamp, Friedegund Meier, Claudia Pfoehler, Dirk Debus, Rudolf Herbst, Carmen Loquai, Frank Meiss, Martin Kaatz, Jens Ulrich, Edgar Dippel, Michael Weichenthal, Axel Hauschild, Ulrike Leiter, Markus V Heppt, Christoffer Gebhardt, Michael Sachse, Fabian Ziller, Stephan Grabbe, Georg Lodde, Maximilian Haist, Friederike Rogall, Yuqi Tan, Imke von Wasielewski, Kai Christian Klespe, Michael Tronnier, and Jan Christoph Simon
- Subjects
Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Background Adjuvant therapy with immune-checkpoint inhibitors (CPI) or BRAF/MEK-directed targeted therapy (TT) improves recurrence-free survival (RFS) for patients with advanced, BRAFV600-mutant (BRAFmut) resected melanoma. However, 40% of these patients will develop distant metastases (DM) within 5 years, which require systemic therapy. Little data exist to guide the choice of upfront adjuvant therapy or treatment management upon DM. This study evaluated the efficacy of subsequent treatments following tumor recurrence upon upfront adjuvant therapy.Methods For this multicenter cohort study, we identified 515 BRAFmut patients with resected stage III melanoma who were treated with PD-1 inhibitors (anti-PD1) or TT in the adjuvant setting. Disease characteristics, treatment regimens, details on tumor recurrence, subsequent treatment management, and survival outcomes were collected within the prospective, real-world skin cancer registry ADOReg. Primary endpoints included progression-free survival (PFS) following DM and best tumor response to first-line (1L) treatments.Results Among 515 eligible patients, 273 patients received adjuvant anti-PD1 and 242 adjuvant TT. At a median follow-up of 21 months, 54.6% of anti-PD1 patients and 36.4% of TT patients recurred, while 39.6% (anti-PD1) and 29.3% (TT) developed DM. Risk of recurrence was significantly reduced in patients treated with TT compared with anti-PD1 (adjusted HR 0.52; 95% CI 0.40 to 0.68, p
- Published
- 2023
- Full Text
- View/download PDF
3. Brain metastasis and survival outcomes after first-line therapy in metastatic melanoma: a multicenter DeCOG study on 1704 patients from the prospective skin cancer registry ADOREG
- Author
-
Dirk Schadendorf, Lucie Heinzerling, Jessica C Hassel, Lisa Zimmer, Ralf Gutzmer, Alexander Kreuter, Andrea Forschner, Elisabeth Livingstone, Bastian Schilling, Selma Ugurel, Peter Mohr, Thilo Gambichler, Patrick Terheyden, Sebastian Haferkamp, Friedegund Meier, Claudia Pfoehler, Dirk Debus, Rudolf Herbst, Carmen Loquai, Frank Meiss, Carsten Weishaupt, Jochen Utikal, Martin Kaatz, Jens Ulrich, Edgar Dippel, Michael Weichenthal, Maike Trommer, Jürgen Christian Becker, Ulrike Leiter, Cindy Franklin, Christoffer Gebhardt, Katharina Kahler, Leonie Bluhm, Imke Grimmelmann, Marlene Garzarolli, Dorothee Nashan, Michael Sachse, Julia Welzel, Gerhard Weyandt, Susanne Horn, Fabian Ziller, Harald Löffler, Stephan Grabbe, Gaston Schley, Georg Lodde, Jan-Malte Placke, and Anca Sindrilaru
- Subjects
Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Background Despite the availability of effective systemic therapies, a significant number of advanced melanoma patients develops brain metastases. This study investigated differences in incidence and time to diagnosis of brain metastasis and survival outcomes dependent on the type of first-line therapy.Methods Patients with metastatic, non-resectable melanoma (AJCCv8 stage IIIC–V) without brain metastasis at start of first-line therapy (1L-therapy) were identified from the prospective multicenter real-world skin cancer registry ADOREG. Study endpoints were incidence of brain metastasis, brain metastasis-free survival (BMFS), progression-free survival (PFS), and overall survival (OS).Results Of 1704 patients, 916 were BRAF wild-type (BRAFwt) and 788 were BRAF V600 mutant (BRAFmut). Median follow-up time after start of 1L-therapy was 40.4 months. BRAFwt patients received 1L-therapy with immune checkpoint inhibitors (ICI) against CTLA-4+PD-1 (n=281) or PD-1 (n=544). In BRAFmut patients, 1L-therapy was ICI in 415 patients (CTLA-4+PD-1, n=108; PD-1, n=264), and BRAF+MEK targeted therapy (TT) in 373 patients. After 24 months, 1L-therapy with BRAF+MEK resulted in a higher incidence of brain metastasis compared with PD-1±CTLA-4 (BRAF+MEK, 30.3%; CTLA-4+PD-1, 22.2%; PD-1, 14.0%). In multivariate analysis, BRAFmut patients developed brain metastases earlier on 1L-therapy with BRAF+MEK than with PD-1±CTLA-4 (CTLA-4+PD-1: HR 0.560, 95% CI 0.332 to 0.945, p=0.030; PD-1: HR 0.575, 95% CI 0.372 to 0.888, p=0.013). Type of 1L-therapy, tumor stage, and age were independent prognostic factors for BMFS in BRAFmut patients. In BRAFwt patients, tumor stage was independently associated with longer BMFS; ECOG Performance status (ECOG-PS), lactate dehydrogenase (LDH), and tumor stage with OS. CTLA-4+PD-1 did not result in better BMFS, PFS, or OS than PD-1 in BRAFwt patients. For BRAFmut patients, multivariate Cox regression revealed ECOG-PS, type of 1L-therapy, tumor stage, and LDH as independent prognostic factors for PFS and OS. 1L-therapy with CTLA-4+PD-1 led to longer OS than PD-1 (HR 1.97, 95% CI 1.122 to 3.455, p=0.018) or BRAF+MEK (HR 2.41, 95% CI 1.432 to 4.054, p=0.001), without PD-1 being superior to BRAF+MEK.Conclusions In BRAFmut patients 1L-therapy with PD-1±CTLA-4 ICI resulted in a delayed and less frequent development of brain metastasis compared with BRAF+MEK TT. 1L-therapy with CTLA-4+PD-1 showed superior OS compared with PD-1 and BRAF+MEK. In BRAFwt patients, no differences in brain metastasis and survival outcomes were detected for CTLA-4+PD-1 compared with PD-1.
- Published
- 2023
- Full Text
- View/download PDF
4. COMBI-r: A Prospective, Non-Interventional Study of Dabrafenib Plus Trametinib in Unselected Patients with Unresectable or Metastatic BRAF V600-Mutant Melanoma
- Author
-
Carola Berking, Elisabeth Livingstone, Dirk Debus, Carmen Loquai, Michael Weichenthal, Ulrike Leiter, Felix Kiecker, Peter Mohr, Thomas K. Eigentler, Janina Remy, Katharina Schober, Markus V. Heppt, Imke von Wasielewski, Dirk Schadendorf, and Ralf Gutzmer
- Subjects
melanoma ,BRAF mutation ,MAPK pathway ,dabrafenib ,trametinib ,brain metastases ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Combined BRAF/MEK-inhibition constitutes a relevant treatment option for BRAF-mutated advanced melanoma. The prospective, non-interventional COMBI-r study assessed the effectiveness and tolerability of the BRAF-inhibitor dabrafenib combined with the MEK-inhibitor trametinib in patients with advanced melanoma under routine clinical conditions. Progression-free survival (PFS) was the primary objective, and secondary objectives included overall survival (OS), disease control rate, duration of therapy, and the frequency and severity of adverse events. This study enrolled 472 patients at 55 German sites. The median PFS was 8.3 months (95%CI 7.1–9.3) and the median OS was 18.3 months (14.9–21.3), both tending to be longer in pre-treated patients. In the 147 patients with CNS metastases, PFS was similar in those requiring corticosteroids (probably representing symptomatic patients, 5.6 months (3.9–7.2)) compared with those not requiring corticosteroids (5.9 months (4.8–6.9)); however, OS was shorter in patients with brain metastases who received corticosteroids (7.8 (6.3–11.6)) compared to those who did not (11.9 months (9.6–19.5)). The integrated subjective assessment of tumor growth dynamics proved helpful to predict outcome: investigators’ upfront categorization correlated well with time-to-event outcomes. Taken together, COMBI-r mirrored PFS outcomes from other prospective, observational studies and confirmed efficacy and safety findings from the pivotal phase III COMBI-d/-v and COMBI-mb trials.
- Published
- 2023
- Full Text
- View/download PDF
5. Impact of radiotherapy and sequencing of systemic therapy on survival outcomes in melanoma patients with previously untreated brain metastasis: a multicenter DeCOG study on 450 patients from the prospective skin cancer registry ADOREG
- Author
-
Dirk Schadendorf, Lucie Heinzerling, Lisa Zimmer, Ralf Gutzmer, Alexander Kreuter, Andrea Forschner, Elisabeth Livingstone, Selma Ugurel, Alexander Roesch, Peter Mohr, Thilo Gambichler, Patrick Terheyden, Sebastian Haferkamp, Friedegund Meier, Claudia Pfoehler, Dirk Debus, Rudolf Herbst, Frank Meiss, Carsten Weishaupt, Jochen Utikal, Martin Kaatz, Jens Ulrich, Edgar Dippel, Michael Weichenthal, Maike Trommer, Ulrike Leiter, Kerstin Schatton, Cindy Franklin, Leonie Bluhm, Imke Grimmelmann, Marlene Garzarolli, Dorothee Nashan, Michael Sachse, Julia Welzel, Gerhard Weyandt, Eren Celik, Iris Helfrich, and Susanne Horn
- Subjects
Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Published
- 2022
- Full Text
- View/download PDF
6. Combined immunotherapy with nivolumab and ipilimumab with and without local therapy in patients with melanoma brain metastasis: a DeCOG* study in 380 patients
- Author
-
Thomas Eigentler, Felix Kiecker, Sarah Schaefer, Henner Stege, Katharina Kaehler, Sebastian Haferkamp, Jochen Uttikal, David Rafei-Shamsabadi, Ante Karoglan, Claudia Pfoehler, Kai Thoms, Dirk Debus, Steffen Emmert, Frank Meiss, Thomas Tueting, and Vanessa Heinrich
- Subjects
Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
BackgroundNivolumab combined with ipilimumab have shown activity in melanoma brain metastasis (MBM). However, in most of the clinical trials investigating immunotherapy in this subgroup, patients with symptomatic MBM and/or prior local brain radiotherapy were excluded. We studied the efficacy of nivolumab plus ipilimumab alone or in combination with local therapies regardless of treatment line in patients with asymptomatic and symptomatic MBM.MethodsPatients with MBM treated with nivolumab plus ipilimumab in 23 German Skin Cancer Centers between April 2015 and October 2018 were investigated. Overall survival (OS) was evaluated by Kaplan-Meier estimator and univariate and multivariate Cox proportional hazard analyses were performed to determine prognostic factors associated with OS.ResultsThree hundred and eighty patients were included in this study and 31% had symptomatic MBM (60/193 with data available) at the time of start nivolumab plus ipilimumab. The median follow-up was 18 months and the 2 years and 3 years OS rates were 41% and 30%, respectively. We identified the following independently significant prognostic factors for OS: elevated serum lactate dehydrogenase and protein S100B levels, number of MBM and Eastern Cooperative Oncology Group performance status. In these patients treated with checkpoint inhibition first-line or later, in the subgroup of patients with BRAFV600-mutated melanoma we found no differences in terms of OS when receiving first-line either BRAF and MEK inhibitors or nivolumab plus ipilimumab (p=0.085). In BRAF wild-type patients treated with nivolumab plus ipilimumab in first-line or later there was also no difference in OS (p=0.996). Local therapy with stereotactic radiosurgery or surgery led to an improvement in OS compared with not receiving local therapy (p=0.009), regardless of the timepoint of the local therapy. Receiving combined immunotherapy for MBM in first-line or at a later time point made no difference in terms of OS in this study population (p=0.119).ConclusionImmunotherapy with nivolumab plus ipilimumab, particularly in combination with stereotactic radiosurgery or surgery improves OS in asymptomatic and symptomatic MBM.
- Published
- 2020
- Full Text
- View/download PDF
7. Discontinuation of BRAF/MEK-Directed Targeted Therapy after Complete Remission of Metastatic Melanoma—A Retrospective Multicenter ADOReg Study
- Author
-
Henner Stege, Maximilian Haist, Michael Schultheis, Maria Isabel Fleischer, Peter Mohr, Friedegund Meier, Dirk Schadendorf, Selma Ugurel, Elisabeth Livingstone, Lisa Zimmer, Rudolf Herbst, Claudia Pföhler, Katharina Kähler, Michael Weichenthal, Patrick Terheyden, Dorothée Nashan, Dirk Debus, Martin Kaatz, Fabian Ziller, Sebastian Haferkamp, Andrea Forschner, Ulrike Leiter, Alexander Kreuter, Jens Ulrich, Johannes Kleemann, Fabienne Bradfisch, Stephan Grabbe, and Carmen Loquai
- Subjects
targeted therapy ,complete response ,advanced melanoma ,discontinuation ,disease progression ,second-line immunotherapy ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
The advent of BRAF/MEK inhibitors (BRAFi/MEKi) has significantly improved progression-free (PFS) and overall survival (OS) for patients with advanced BRAF-V600-mutant melanoma. Long-term survivors have been identified particularly among patients with a complete response (CR) to BRAF/MEK-directed targeted therapy (TT). However, it remains unclear which patients who achieved a CR maintain a durable response and whether treatment cessation might be a safe option in these patients. Therefore, this study investigated the impact of treatment cessation on the clinical course of patients with a CR upon BRAF/MEK-directed-TT. We retrospectively selected patients with BRAF-V600-mutant advanced non-resectable melanoma who had been treated with BRAFi ± MEKi therapy and achieved a CR upon treatment out of the multicentric skin cancer registry ADOReg. Data on baseline patient characteristics, duration of TT, treatment cessation, tumor progression (TP) and response to second-line treatments were collected and analyzed. Of 461 patients who received BRAF/MEK-directed TT 37 achieved a CR. TP after initial CR was observed in 22 patients (60%) mainly affecting patients who discontinued TT (n = 22/26), whereas all patients with ongoing TT (n = 11) maintained their CR. Accordingly, patients who discontinued TT had a higher risk of TP compared to patients with ongoing treatment (p < 0.001). However, our data also show that patients who received TT for more than 16 months and who discontinued TT for other reasons than TP or toxicity did not have a shorter PFS compared to patients with ongoing treatment. Response rates to second-line treatment being initiated in 21 patients, varied between 27% for immune-checkpoint inhibitors (ICI) and 60% for BRAFi/MEKi rechallenge. In summary, we identified a considerable number of patients who achieved a CR upon BRAF/MEK-directed TT in this contemporary real-world cohort of patients with BRAF-V600-mutant melanoma. Sustained PFS was not restricted to ongoing TT but was also found in patients who discontinued TT.
- Published
- 2021
- Full Text
- View/download PDF
8. Real‐world outcomes using <scp>PD</scp> ‐1 antibodies and <scp>BRAF</scp> + <scp>MEK</scp> inhibitors for adjuvant melanoma treatment from 39 skin cancer centers in Germany, Austria and Switzerland
- Author
-
Katharina Schumann, Cornelia Mauch, Kai‐Christian Klespe, Carmen Loquai, Ulrike Nikfarjam, Max Schlaak, Larissa Akçetin, Peter Kölblinger, Magdalena Hoellwerth, Markus Meissner, Guelcin Mengi, Andreas Dominik Braun, Miriam Mengoni, Reinhard Dummer, Joanna Mangana, Mihaela‐Anca Sindrilaru, Dan Radmann, Christine Hafner, Johann Freund, Klemens Rappersberger, Felix Weihsengruber, Frank Meiss, Lydia Reinhardt, Friedegund Meier, Barbara Rainer, Erika Richtig, Julia Maria Ressler, Christoph Höller, Thomas Eigentler, Teresa Amaral, Wiebke K. Peitsch, Uwe Hillen, Wolfgang Harth, Fabian Ziller, Kerstin Schatton, Thilo Gambichler, Laura Susok, Lara Valeska Maul, Heinz Läubli, Dirk Debus, Carsten Weishaupt, Sevil Börger, Katharina Sievers, Sebastian Haferkamp, Veronika Zenderowski, Van Anh Nguyen, Marina Wanner, Ralf Gutzmer, Patrick Terheyden, Katharina Kähler, Steffen Emmert, Alexander Thiem, Michael Sachse, Silke Gercken‐Riedel, Kjell Matthias Kaune, Kai‐Martin Thoms, Lucie Heinzerling, Markus Vincent Heppt, Sabine Tratzmiller, Wolfram Hoetzenecker, Angela Öllinger, Andreas Steiner, Tobias Peinhaupt, Maurizio Podda, Sabine Schmid, Uwe Wollina, Tilo Biedermann, and Christian Posch
- Subjects
Infectious Diseases ,Dermatology - Published
- 2022
9. Brain metastasis and survival outcomes after first-line therapy in metastatic melanoma: a multicenter DeCOG study on 1704 patients from the prospective skin cancer registry ADOREG
- Author
-
Cindy Franklin, Peter Mohr, Leonie Bluhm, Friedegund Meier, Marlene Garzarolli, Michael Weichenthal, Katharina Kähler, Imke Grimmelmann, Ralf Gutzmer, Jochen Utikal, Patrick Terheyden, Rudolf Herbst, Sebastian Haferkamp, Claudia Pfoehler, Andrea Forschner, Ulrike Leiter, Fabian Ziller, Frank Meiss, Jens Ulrich, Alexander Kreuter, Christoffer Gebhardt, Julia Welzel, Bastian Schilling, Martin Kaatz, Karin Scharfetter-Kochanek, Edgar Dippel, Dorothee Nashan, Michael Sachse, Carsten Weishaupt, Harald Löffler, Thilo Gambichler, Carmen Loquai, Lucie Heinzerling, Stephan Grabbe, Dirk Debus, Gaston Schley, Jessica C Hassel, Gerhard Weyandt, Maike Trommer, Georg Lodde, Jan-Malte Placke, Lisa Zimmer, Elisabeth Livingstone, Jürgen Christian Becker, Susanne Horn, Dirk Schadendorf, and Selma Ugurel
- Subjects
Pharmacology ,Cancer Research ,Oncology ,Immunology ,Medizin ,Molecular Medicine ,Immunology and Allergy ,ddc:610 - Abstract
BackgroundDespite the availability of effective systemic therapies, a significant number of advanced melanoma patients develops brain metastases. This study investigated differences in incidence and time to diagnosis of brain metastasis and survival outcomes dependent on the type of first-line therapy.MethodsPatients with metastatic, non-resectable melanoma (AJCCv8 stage IIIC–V) without brain metastasis at start of first-line therapy (1L-therapy) were identified from the prospective multicenter real-world skin cancer registry ADOREG. Study endpoints were incidence of brain metastasis, brain metastasis-free survival (BMFS), progression-free survival (PFS), and overall survival (OS).ResultsOf 1704 patients, 916 were BRAF wild-type (BRAFwt) and 788 were BRAF V600 mutant (BRAFmut). Median follow-up time after start of 1L-therapy was 40.4 months. BRAFwtpatients received 1L-therapy with immune checkpoint inhibitors (ICI) against CTLA-4+PD-1 (n=281) or PD-1 (n=544). In BRAFmutpatients, 1L-therapy was ICI in 415 patients (CTLA-4+PD-1, n=108; PD-1, n=264), and BRAF+MEK targeted therapy (TT) in 373 patients. After 24 months, 1L-therapy with BRAF+MEK resulted in a higher incidence of brain metastasis compared with PD-1±CTLA-4 (BRAF+MEK, 30.3%; CTLA-4+PD-1, 22.2%; PD-1, 14.0%). In multivariate analysis, BRAFmutpatients developed brain metastases earlier on 1L-therapy with BRAF+MEK than with PD-1±CTLA-4 (CTLA-4+PD-1: HR 0.560, 95% CI 0.332 to 0.945, p=0.030; PD-1: HR 0.575, 95% CI 0.372 to 0.888, p=0.013). Type of 1L-therapy, tumor stage, and age were independent prognostic factors for BMFS in BRAFmutpatients. In BRAFwtpatients, tumor stage was independently associated with longer BMFS; ECOG Performance status (ECOG-PS), lactate dehydrogenase (LDH), and tumor stage with OS. CTLA-4+PD-1 did not result in better BMFS, PFS, or OS than PD-1 in BRAFwtpatients. For BRAFmutpatients, multivariate Cox regression revealed ECOG-PS, type of 1L-therapy, tumor stage, and LDH as independent prognostic factors for PFS and OS. 1L-therapy with CTLA-4+PD-1 led to longer OS than PD-1 (HR 1.97, 95% CI 1.122 to 3.455, p=0.018) or BRAF+MEK (HR 2.41, 95% CI 1.432 to 4.054, p=0.001), without PD-1 being superior to BRAF+MEK.ConclusionsIn BRAFmutpatients 1L-therapy with PD-1±CTLA-4 ICI resulted in a delayed and less frequent development of brain metastasis compared with BRAF+MEK TT. 1L-therapy with CTLA-4+PD-1 showed superior OS compared with PD-1 and BRAF+MEK. In BRAFwtpatients, no differences in brain metastasis and survival outcomes were detected for CTLA-4+PD-1 compared with PD-1.
- Published
- 2023
10. CLAUDIUS Study: Risk of Materno-Fetal Transmission of Melanoma Cells in Pregnant Women with High Grade Melanoma – A Retrospective Multicenter Study and Literature Review
- Author
-
Svenja Vanessa Wiedemann, Verena Müller, Bettina Toth, Michael Erdmann, Bodo Bühler, Susanne Dugas-Breit, Kerstin Schatton, Lydia Reinhardt, Markus Meissner, Marion Mickler, Claudia Pföhler, Carsten Weishaupt, Rudolf Herbst, Dirk Debus, Laura Susok, Julia Katharina Tietze, Julia Welzel, Andreas Arnold, Evelyn Dabrowski, Andrea Forschner, Steven Goetze, Kinan Hayani, Céleste Lebbe, Florian Löhr, Miriam Mengoni, Barbara Hermes, Wiebke Katharina Peitsch, Gabriela Poch, Michael Sachse, Anca Sindrilaru, Saskia Wenk, Mirjana Ziemer, Kjell Kaune, Lisette Meier-Naust, Georgios Nikolakis, Florian Oberndörfer, Ulrich Wesselmann, Jochen Utikal, and Maria Rita Gaiser
- Published
- 2023
11. Lipase elevation and type 1 diabetes mellitus related to immune checkpoint inhibitor therapy – A multicentre study of 90 patients from the German Dermatooncology Group
- Author
-
Michael Momma, Carmen Loquai, Cristel Ruini, Corinna Kochanek, Kai-Martin Thoms, Selma Ugurel, Carola Berking, Lisa Zimmer, Friedegund Meier, Katharina C. Kähler, Lucie Heinzerling, Dirk Debus, Jessica C. Hassel, Imke Grimmelmann, Claudia Pföhler, Jochen Utikal, Rudolf A. Herbst, Thomas Eigentler, and Ralf Gutzmer
- Subjects
Adult ,Blood Glucose ,Male ,0301 basic medicine ,Cancer Research ,medicine.medical_specialty ,Skin Neoplasms ,Time Factors ,Medizin ,Gastroenterology ,Thyroiditis ,Young Adult ,03 medical and health sciences ,0302 clinical medicine ,Predictive Value of Tests ,Germany ,Internal medicine ,Diabetes mellitus ,medicine ,Humans ,Lipase ,Adverse effect ,Immune Checkpoint Inhibitors ,Melanoma ,Aged ,Retrospective Studies ,Aged, 80 and over ,Type 1 diabetes ,biology ,business.industry ,Diabetes ,Immune checkpoint inhibitors ,Immune-related adverse events ,Ipilimumab ,Nivolumab ,Pancreatitis ,PD-1 inhibitor ,Pembrolizumab ,Biomarkers ,Diabetes Mellitus, Type 1 ,Exocrine Pancreatic Insufficiency ,Female ,Middle Aged ,Treatment Outcome ,Up-Regulation ,medicine.disease ,Ketoacidosis ,030104 developmental biology ,Oncology ,030220 oncology & carcinogenesis ,biology.protein ,Skin cancer ,business - Abstract
Aim Immune checkpoint inhibition (ICI) triggers immune-related adverse events (irAEs). The relevance of lipase elevation remains unclear. Patients and methods Skin cancer patients with newly detected serum lipase elevation (at least twofold upper normal limit) or newly diagnosed type I diabetes mellitus upon ICI therapy were retrospectively collected at 14 German skin cancer centres. Results We identified 68 patients with lipase elevation occurring after a median time of 19 (range 1–181) weeks on ICI, 15 (22%) thereof had symptoms consistent with pancreatitis. Forty-seven patients (73%) had other irAE, mainly colitis. Discontinuation (n = 24, 35%) or interruption (n = 26, 38%) of ICI resulted in decrease of lipase after reinduction of ICI lipase levels increased again in 12 of 24 patients. In 18 patients (27%), ICI was continued unchanged, and in 12 (67%) of them, lipase levels normalised. Twenty-two patients were identified with newly diagnosed type I diabetes mellitus related to ICI, and 12 (55%) thereof had also lipase elevation mainly shortly before or after the diagnosis of diabetes. Fourteen (64%) patients had other irAE, mainly thyroiditis. Irrespective of lipase elevation, patients frequently showed a rapid onset with ketoacidosis, decreased c-peptide, and strongly increased blood glucose levels. Conclusion Increased serum lipase during ICI is often not associated with pancreatitis but with other irAE as possible cause. Therefore, it might be sufficient to regularly monitor blood glucose levels and perform further workup only in case of signs or symptoms of pancreatitis and/or exocrine pancreas insufficiency.
- Published
- 2021
12. Malignes Melanom
- Author
-
Lucia Peeken, Dirk Debus, and Erwin Schultz
- Subjects
Anesthesiology and Pain Medicine ,General Medicine - Published
- 2021
13. Patterns of care and follow-up care of patients with uveal melanoma in German-speaking countries: a multinational survey of the German Dermatologic Cooperative Oncology Group (DeCOG)
- Author
-
Peter Elsner, Cornelia Mauch, Lisa Zimmer, Mareike Alter, Alexander Enk, Friedegund Meier, Matthias Goebeler, Verena Müller, Mirjana Ziemer, Konstantin Drexler, Claudia Pföhler, Sebastian Haferkamp, Jessica C. Hassel, Christiane Bayerl, Katharina C. Kähler, Markus Zutt, Markus Streit, Nicole Kreuzberg, Thomas Tüting, Patrick Terheyden, Christiane Pfeiffer, Carmen Loquai, Dirk Debus, Nina Devereux, Ahn Van Nguyen, Elisabeth Livingstone, Rainer Rompel, Christian Posch, Steffen Emmert, Ulrich Wesselmann, Evelyn Dabrowski, Matthias Schmuth, Max Schlaak, Anja Wessely, Christoffer Gebhardt, Anja Gesierich, Gesina Hansel, Theresa Steeb, Uwe Wollina, Julia Welzel, Erwin S. Schultz, Reinhard Dummer, Jan C. Simon, Hans-Joachim Schulze, Ralf Gutzmer, Michael Max Sachse, Rose K. C. Moritz, Steven Goetze, J. Mangana, Lara Valeska Maul, Markus V. Heppt, Harald Löffler, Kjell M. Kaume, Wolfgang Krapf, Percy Lehmann, Carola Berking, Stefanie Sauder, Alexander A. Navarini, Edgar Dippel, Bastian Schilling, Markus Meissner, Alexander Thiem, Dirk Schadendorf, Pia Dücker, Sergij Goerdt, Gerhard Weyandt, Lucie Heinzerling, Kerstin Schatton, Erika Richtig, Guido Bruning, Armin Bender, and Peter Mohr
- Subjects
Uveal Neoplasms ,0301 basic medicine ,Cancer Research ,Skin Neoplasms ,Cross-sectional study ,Original Article – Clinical Oncology ,Patterns of care ,Medizin ,Aftercare ,Disease ,German ,Uveal melanoma ,0302 clinical medicine ,Germany ,Surveys and Questionnaires ,Mass Screening ,Neoplasm Metastasis ,Practice Patterns, Physicians' ,Melanoma ,Referral and Consultation ,Treatment patterns ,Surveillance ,Follow-up ,Ocular melanoma ,General Medicine ,ddc ,Oncology ,Austria ,Population Surveillance ,030220 oncology & carcinogenesis ,language ,Switzerland ,medicine.medical_specialty ,Ocular Melanoma ,03 medical and health sciences ,medicine ,Humans ,ddc:610 ,Monitoring, Physiologic ,Health Services Needs and Demand ,business.industry ,Cancer ,Guideline ,medicine.disease ,language.human_language ,Background ,Cross-Sectional Studies ,030104 developmental biology ,Family medicine ,Neoplasm Recurrence, Local ,Skin cancer ,business ,Follow-Up Studies - Abstract
Purpose Uveal melanoma (UM) is an orphan cancer of high unmet medical need. Current patterns of care and surveillance remain unclear as they are situated in an interdisciplinary setting. Methods A questionnaire addressing the patterns of care and surveillance in the management of patients with uveal melanoma was distributed to 70 skin cancer centers in Austria, Germany and Switzerland. Frequency distributions of responses for each item of the questionnaire were calculated. Results 44 of 70 (62.9%) skin cancer centers completed the questionnaire. Thirty-nine hospitals were located in Germany (88.6%), three in Switzerland (6.8%) and two in Austria (4.5%). The majority (68.2%) represented university hospitals. Most patients with metastatic disease were treated in certified skin cancer centers (70.7%, 29/41). Besides, the majority of patients with UM were referred to the respective skin cancer center by ophthalmologists (87.2%, 34/39). Treatment and organization of follow-up of patients varied across the different centers. 35.1% (14/37) of the centers stated to not perform any screening measures. Conclusion Treatment patterns of patients with uveal melanoma in Germany, Austria and Switzerland remain extremely heterogeneous. A guideline for the treatment and surveillance is urgently needed.
- Published
- 2020
14. MAPKinase inhibition after failure of immune checkpoint blockade in patients with advanced melanoma - An evaluation of the multicenter prospective skin cancer registry ADOREG
- Author
-
Sophia Kreft, Valerie Glutsch, Anne Zaremba, Patrick Schummer, Peter Mohr, Imke Grimmelmann, Ralf Gutzmer, Friedegund Meier, Claudia Pföhler, Michael Max Sachse, Frank Meiss, Andrea Forschner, Sebastian Haferkamp, Julia Welzel, Patrick Terheyden, Rudolf Herbst, Jochen Utikal, Martin Kaatz, Carsten Weishaupt, Alexander Kreuter, Dirk Debus, Pia Duecker, Anca Sindrilaru, Harald Löffler, Gaston Schley, Michael Weichenthal, Dirk Schadendorf, Selma Ugurel, Anja Gesierich, and Bastian Schilling
- Subjects
Mitogen-Activated Protein Kinase Kinases ,Proto-Oncogene Proteins B-raf ,Cancer Research ,Skin Neoplasms ,Brain Neoplasms ,Programmed Cell Death 1 Receptor ,Medizin ,Ipilimumab ,Nivolumab ,Oncology ,Antineoplastic Combined Chemotherapy Protocols ,Humans ,ddc:610 ,Prospective Studies ,Registries ,Immune Checkpoint Inhibitors ,Melanoma ,Retrospective Studies - Abstract
Objectives: Forty to sixty percent of patients with advanced melanoma show primary resistance to PD-1-based immunotherapy, 30–40% of initial responders also progress. Here, we evaluated the outcome of second-line targeted therapy (TT) after progression on PD-1-based immune checkpoint inhibition (ICI) in BRAFV600-mutated melanoma. In addition, we report data on the activity of re-exposure with PD-1-based regimes. Methods: Patients with advanced (non-resectable stage III or IV, AJCC 2017, 8th edition) melanoma progressing on PD-1-based ICI (nivolumab, pembrolizumab or ipilimumab plus nivolumab) and receiving second-line BRAF plus MEK inhibition were identified from the prospective multicenter skin cancer registry ADOREG. Results: We identified 108 patients with unresectable stage III or stage IV melanoma progressing on first-line ICI (nivolumab, pembrolizumab or ipilimumab plus nivolumab) and receiving second-line combined BRAF/MEK inhibition. Seventy-three percent of the cohort presented with primary PD-1 resistant disease. Median progression-free survival (PFS) on ICI was 2.6 (95% CI 2.2–2.9) months. Median PFS on subsequent TT was 6.6 (95% CI 5.4–7.8) months. Median OS from start of second-line TT was 16.0 (95% CI 11.2–20.8) months. The 3-year PFS and OS rates on second-line TT were 16% and 30%. The objective response rate (ORR) and disease control rate (DCR) to TT were 42.6% and 55.6%. In patients with brain metastases, the ORR and DCR were 31.4% and 43.1%. Patients without brain metastases showed an ORR and DCR of 52.6% and 66.7%, respectively. Response to first-line ICI was associated with a numerically higher ORR and DCR to second-line TT and improved OS on TT. Twenty-three patients received third-line ICI of whom two patients showed an objective response. Conclusions: BRAF plus MEK inhibition shows meaningful activity and outcome in patients with advanced melanoma resistant to anti-PD-1-based immunotherapy. Rates of long-term benefit and survival in our study were similar to those reported for treatment-naïve patients receiving first-line MAPKi.
- Published
- 2022
15. Impact of radiotherapy and sequencing of systemic therapy on survival outcomes in melanoma patients with previously untreated brain metastasis : a multicenter DeCOG study on 450 patients from the prospective skin cancer registry ADOREG
- Author
-
Cindy Franklin, Peter Mohr, Leonie Bluhm, Imke Grimmelmann, Ralf Gutzmer, Friedegund Meier, Marlene Garzarolli, Michael Weichenthal, Claudia Pfoehler, Rudolf Herbst, Patrick Terheyden, Jochen Utikal, Jens Ulrich, Dirk Debus, Sebastian Haferkamp, Martin Kaatz, Andrea Forschner, Ulrike Leiter, Dorothee Nashan, Alexander Kreuter, Michael Sachse, Julia Welzel, Lucie Heinzerling, Frank Meiss, Carsten Weishaupt, Thilo Gambichler, Gerhard Weyandt, Edgar Dippel, Kerstin Schatton, Eren Celik, Maike Trommer, Iris Helfrich, Alexander Roesch, Lisa Zimmer, Elisabeth Livingstone, Dirk Schadendorf, Susanne Horn, and Selma Ugurel
- Subjects
Pharmacology ,Mitogen-Activated Protein Kinase Kinases ,Proto-Oncogene Proteins B-raf ,Cancer Research ,Skin Neoplasms ,Brain Neoplasms ,Immunology ,Programmed Cell Death 1 Receptor ,Medizin ,Oncology ,Molecular Medicine ,Immunology and Allergy ,Humans ,CTLA-4 Antigen ,ddc:610 ,Prospective Studies ,Registries ,Melanoma ,Aged - Abstract
BackgroundDespite of various therapeutic strategies, treatment of patients with melanoma brain metastasis (MBM) still is a major challenge. This study aimed at investigating the impact of type and sequence of immune checkpoint blockade (ICB) and targeted therapy (TT), radiotherapy, and surgery on the survival outcome of patients with MBM.MethodWe assessed data of 450 patients collected within the prospective multicenter real-world skin cancer registry ADOREG who were diagnosed with MBM before start of the first non-adjuvant systemic therapy. Study endpoints were progression-free survival (PFS) and overall survival (OS).ResultsOf 450 MBM patients, 175 (38.9%) received CTLA-4+PD-1 ICB, 161 (35.8%) PD-1 ICB, and 114 (25.3%) BRAF+MEK TT as first-line treatment. Additional to systemic therapy, 67.3% of the patients received radiotherapy (stereotactic radiosurgery (SRS); conventional radiotherapy (CRT)) and 24.4% had surgery of MBM. 199 patients (42.2%) received a second-line systemic therapy. Multivariate Cox regression analysis revealed the application of radiotherapy (HR for SRS: 0.213, 95% CI 0.094 to 0.485, p1 cm: 1.977, 95% CI 1.117 to 3.500, p=0.019), age (HR for age >65 years: 1.802, 95% CI 1.016 to 3.197, p=0.044), and ECOG performance status (HR for ECOG ≥2: HR: 2.615, 95% CI 1.024 to 6.676, p=0.044) as independent prognostic factors of OS on first-line therapy. The type of first-line therapy (ICB vs TT) was not independently prognostic. As second-line therapy BRAF+MEK showed the best survival outcome compared with ICB and other therapies (HR for CTLA-4+PD-1 compared with BRAF+MEK: 13.964, 95% CI 3.6 to 54.4, pConclusionsIn patients with MBM, the addition of radiotherapy resulted in a favorable OS on systemic therapy. In BRAF-mutated MBM patients, ICB as first-line therapy and BRAF+MEK as second-line therapy were associated with a significantly prolonged OS.
- Published
- 2022
16. Patients with BRAF-Mutant Advanced/Metastatic Melanoma: Original Research on the Treatment Reality in Germany and Austria in the Era of Choice
- Author
-
Bastian Schilling, Thomas Haalck, Sebastian Haferkamp, Jochen Utikal, Patrick Terheyden, Mareike Alter, Andreas Pinter, Ingrid H. Wolf, Michael Max Sachse, and Dirk Debus
- Subjects
Adult ,Male ,Proto-Oncogene Proteins B-raf ,Oncology ,medicine.medical_specialty ,Skin Neoplasms ,Pyridones ,medicine.medical_treatment ,Antineoplastic Agents ,Pyrimidinones ,Disease ,Targeted therapy ,Young Adult ,Germany ,Internal medicine ,Oximes ,Humans ,Medicine ,Pharmacology (medical) ,Molecular Targeted Therapy ,Neoplasm Metastasis ,Melanoma ,Survival rate ,Aged ,Retrospective Studies ,Aged, 80 and over ,Trametinib ,business.industry ,Imidazoles ,Dabrafenib ,General Medicine ,Middle Aged ,medicine.disease ,Discontinuation ,Cross-Sectional Studies ,Austria ,Practice Guidelines as Topic ,Cutaneous melanoma ,Female ,business ,medicine.drug - Abstract
Cutaneous melanoma is one of the most aggressive forms of skin neoplasms and represents a major cause of neoplastic or cancer death in Europe. Without adequate therapy, the 5-year survival rate is 15% when the disease metastasizes to distant organs. The objective of our study was to evaluate the status quo of the current treatment standards in stage IV melanoma and rationale for therapy decisions in Germany and Austria between January 2016 and September 2018. In this retrospective, anonymized registry, data of male and female patients with unresectable advanced/metastatic BRAF-positive cutaneous melanoma treated in the first, second, and third line with registered substances were analyzed using descriptive statistics. Ninety-nine patients (50.5% male) received a total of 172 treatment lines. The first (99 patients), second (56 patients), and third (17 patients) treatment lines were documented. Within the 80.8% of patients with stage IV melanoma, targeted therapy (TT) was more frequently administered as a first-line treatment than immunotherapy (IO) with checkpoint inhibitors (59.6% TT vs. 40.4% IO). Across all lines, patients received TT in 54.7% and IO in 43.0% of the cases. As targeted agents, dabrafenib plus trametinib was predominantly prescribed (72.3%), whereas the monotherapy with anti-programmed cell death protein 1 and anti-cytotoxic T lymphocyte-associated protein 4 antibodies or their combination was prescribed similarly often (50.0% vs. 47.3%). Most commonly, the treatment type was switched from TT to IO or vice versa upon disease progression. The most frequent rationales for prescribing either TT or IO were remission pressure (72.9%) or physician’s preference (45.0%), respectively. Disease progression was a more frequent cause of treatment discontinuation than undesired events. Patients in Germany and Austria with unresectable advanced or metastatic BRAF-mutant melanoma predominantly receive guideline-recommended treatments. TT was more frequently administered than IO while the rationale for prescribing a specific treatment type differed between the two.
- Published
- 2020
17. Das maligne Melanom
- Author
-
Erwin S. Schultz, Dirk Debus, and Manuel Krieter
- Subjects
Gynecology ,medicine.medical_specialty ,business.industry ,Melanoma ,Follow up studies ,General Medicine ,030204 cardiovascular system & hematology ,medicine.disease ,Follow up care ,03 medical and health sciences ,0302 clinical medicine ,medicine ,030212 general & internal medicine ,Differential diagnosis ,business ,Melanoma diagnosis - Abstract
Wegen seiner fruhzeitigen Metastasierung ist beim malignen Melanom eine rasche Diagnosestellung von zentraler Bedeutung. Ist der „schwarze Hautkrebs“ erst erkannt, sind weitere diagnostische und therapeutische Schritte notwendig, die sich an genau definierten Algorithmen orientieren. Auf den Gebieten der adjuvanten und metastasierten Situation haben in den letzten Jahren neue Erkenntnisse zu grundlegenden Anderungen des Therapieregimes gefuhrt. Mit diesem Artikel soll eine Ubersicht uber das aktuelle leitlinienorientierte Vorgehen beim malignen Melanom gegeben werden.
- Published
- 2019
18. Encorafenib plus binimetinib in patients with locally advanced, unresectable, or metastatic BRAFV600-mutant melanoma: Updated data from the multicenter, multinational, prospective, non-interventional longitudinal study BERINGMELANOMA
- Author
-
Erika Richtig, Carmen Loquai, Andrea Forschner, Ralf Gutzmer, Jessica Cecile Hassel, Jochen Utikal, Sebastian Haferkamp, Friedegund Elke Meier, Dirk Debus, Reinhard Dummer, Roger Anton Fredy Von Moos, Jan Thompson, Laura Gengenbacher, Olivier Michielin, Christoph Hoeller, and Dirk Schadendorf
- Subjects
Cancer Research ,Oncology - Abstract
9526 Background: For the treatment of advanced BRAFV600-mutated melanoma, targeted BRAF/MEK-inhibition is a standard of care. Encorafenib + binimetinib (EB) were approved 2018 in the EU and 2019 in Switzerland, based on positive results from COLUMBUS (NCT01909453), median progression-free survival (PFS) 14.9 mo (5-yr PFS: 23%), overall survival (OS) 33.6 mo (5-yr OS: 35%). As data from controlled trials are based on selected populations, BERINGMELANOMA investigates EB-use under real-world conditions in a broader population. Methods: BERINGMELANOMA (NCT04045691) is an ongoing, multi-national, prospective, longitudinal, non-interventional study. It analyzes the effectiveness (prim. endpoint: 1-yr PFS-rate), QoL and safety of EB-therapy in the unresectable advanced or metastatic setting under real-world conditions, focusing on the first- (1L) and second-line setting including an evaluation of the impact of prognostic factors. The project aims to enroll up to 750 patients (pts) in a total of 80 German, Austrian and Swiss sites (study duration: 8 yrs). So far (10/2019-01/2022), 280 pts have been included. Pts with prior BRAF-/MEK-inhibition (except adjuvant use completed > 6 mo) and > 1 prior therapy line with CPI in the palliative setting were excluded (adjuvant CPI allowed). Results: Here we present the 2nd planned interim snapshot based on the initial 200 enrolled pts (186 treated / 182 evaluable; median FU: 14.2 mo). This analysis set shows a median age of 60.5 yrs (range 20.0-89.0), 45% of pts were female. 87% presented with distant metastases (brain: 30%), with an involvement of ≥3 organ systems in 51% and elevated LDH in 43%. 54% of pts underwent any prior systemic therapy (adjuvant: 30%; 1L CPI palliative: 24%, mainly with ipilimumab + nivolumab). EB was mainly administered in the 1L-setting (60%). Main reasons for EB-selection were: efficacy (44%), physician's preference (34%), QoL (17%). Median estimated EB treatment duration was 11.6 mo (95%CI 8.8-18.6), median relative dose intensity for both drugs: 100%, main reasons EB-discontinuation: PD (55%), toxicity (16%). Treatment adaptations were required in 40% of pts (interruption E 26%, B 29%), toxicity as main reason (E 26%, B 29%). Adverse events were reported in 86% of pts (grade 3/4: 34%), mainly (≥10%, all grades): diarrhea, nausea, fatigue (each 17%), CK increase (16%), GGT increase (11%). No fatal toxicities were observed. Conclusions: This 2nd interim snapshot shows an investigation of EB in a real-world population with advanced disease. Despite the poorer prognosis configuration as compared to the pivotal study, the observed tolerability profile is largely consistent with data derived from COLUMBUS without any new safety signals. The 3rd interim snapshot will be performed after enrollment of 300 pts.
- Published
- 2022
19. Surveillance of patients with conjunctival melanoma in German-speaking countries: a multinational survey of the German dermatologic cooperative oncology group
- Author
-
Anja Wessely, Theresa Steeb, Carola Berking, Max Schlaak, Markus V. Heppt, Mareike Alter, Christiane Bayerl, Armin Bender, Guido Bruning, Evelyn Dabrowski, Dirk Debus, Nina Devereux, Edgar Dippel, Konstantin Drexler, Pia Dücker, Reinhard Dummer, Steffen Emmert, Peter Elsner, Alexander Enk, Christoffer Gebhardt, Anja Gesierich, Matthias Goebeler, Sergij Goerdt, Steven Goetze, Ralf Gutzmer, Sebastian Haferkamp, Gesina Hansel, Jessica C. Hassel, Lucie Heinzerling, Katharina C. Kähler, Kjell M. Kaume, Wolfgang Krapf, Nicole Kreuzberg, Percy Lehmann, Elisabeth Livingstone, Harald Löffler, Carmen Loquai, Cornelia Mauch, Johanna Mangana, Friedegund Meier, Markus Meissner, Rose K.C. Moritz, Lara Valeska Maul, Verena Müller, Peter Mohr, Alexander Navarini, Ahn Van Nguyen, Christiane Pfeiffer, Claudia Pföhler, Christian Posch, Erika Richtig, Rainer Rompel, Michael M. Sachse, Stefanie Sauder, Dirk Schadendorf, Kerstin Schatton, Hans-Joachim Schulze, Erwin Schultz, Bastian Schilling, Matthias Schmuth, Jan C. Simon, Markus Streit, Patrick Terheyden, Alexander Thiem, Thomas Tüting, Julia Welzel, Gerhard Weyandt, Ulrich Wesselmann, Uwe Wollina, Mirjana Ziemer, Lisa Zimmer, and Markus Zutt
- Subjects
Cancer Research ,medicine.medical_specialty ,business.industry ,MEDLINE ,Medizin ,language.human_language ,German ,Cross-Sectional Studies ,Oncology ,Multinational corporation ,Germany ,Surveys and Questionnaires ,Family medicine ,medicine ,language ,Humans ,business ,Conjunctiva ,Melanoma ,Conjunctival Melanoma - Published
- 2021
20. Discontinuation of braf/mek-directed targeted therapy after complete remission of metastatic melanoma : a retrospective multicenter adoreg study
- Author
-
Alexander Kreuter, Maximilian Haist, Fabienne Bradfisch, Carmen Loquai, Andrea Forschner, Friedegund Meier, Dorothee Nashan, Peter Mohr, Ulrike Leiter, Martin Kaatz, Claudia Pföhler, Rudolf A. Herbst, Stephan Grabbe, Michael Weichenthal, Maria Isabel Fleischer, Fabian Ziller, Dirk Schadendorf, Johannes Kleemann, Patrick Terheyden, Henner Stege, Lisa Zimmer, Sebastian Haferkamp, Jens Ulrich, Katharina C. Kähler, Selma Ugurel, Michael Schultheis, Dirk Debus, and Elisabeth Livingstone
- Subjects
0301 basic medicine ,Oncology ,advanced melanoma ,Cancer Research ,medicine.medical_specialty ,medicine.medical_treatment ,Medizin ,Article ,Targeted therapy ,complete response ,03 medical and health sciences ,0302 clinical medicine ,disease progression ,Internal medicine ,Medicine ,ddc:610 ,second-line immunotherapy ,neoplasms ,Complete response ,RC254-282 ,business.industry ,Melanoma ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,medicine.disease ,targeted therapy ,Discontinuation ,030104 developmental biology ,Tumor progression ,030220 oncology & carcinogenesis ,Toxicity ,Cohort ,Skin cancer ,business ,discontinuation - Abstract
The advent of BRAF/MEK inhibitors (BRAFi/MEKi) has significantly improved progression-free (PFS) and overall survival (OS) for patients with advanced BRAF-V600-mutant melanoma. Long-term survivors have been identified particularly among patients with a complete response (CR) to BRAF/MEK-directed targeted therapy (TT). However, it remains unclear which patients who achieved a CR maintain a durable response and whether treatment cessation might be a safe option in these patients. Therefore, this study investigated the impact of treatment cessation on the clinical course of patients with a CR upon BRAF/MEK-directed-TT. We retrospectively selected patients with BRAF-V600-mutant advanced non-resectable melanoma who had been treated with BRAFi ± MEKi therapy and achieved a CR upon treatment out of the multicentric skin cancer registry ADOReg. Data on baseline patient characteristics, duration of TT, treatment cessation, tumor progression (TP) and response to second-line treatments were collected and analyzed. Of 461 patients who received BRAF/MEK-directed TT 37 achieved a CR. TP after initial CR was observed in 22 patients (60%) mainly affecting patients who discontinued TT (n = 22/26), whereas all patients with ongoing TT (n = 11) maintained their CR. Accordingly, patients who discontinued TT had a higher risk of TP compared to patients with ongoing treatment (p <, 0.001). However, our data also show that patients who received TT for more than 16 months and who discontinued TT for other reasons than TP or toxicity did not have a shorter PFS compared to patients with ongoing treatment. Response rates to second-line treatment being initiated in 21 patients, varied between 27% for immune-checkpoint inhibitors (ICI) and 60% for BRAFi/MEKi rechallenge. In summary, we identified a considerable number of patients who achieved a CR upon BRAF/MEK-directed TT in this contemporary real-world cohort of patients with BRAF-V600-mutant melanoma. Sustained PFS was not restricted to ongoing TT but was also found in patients who discontinued TT.
- Published
- 2021
21. Intervalltherapie mit Vemurafenib beim malignen Melanom
- Author
-
M. Huber, Karin Scharffetter‐Kochanek, Nicolai Treiber, Dirk Debus, Lars Alexander Schneider, and Erwin S. Schultz
- Subjects
Text mining ,business.industry ,Cancer research ,Medicine ,Dermatology ,business - Published
- 2017
22. Intermittent vemurafenib therapy in malignant melanoma
- Author
-
Karin Scharffetter-Kochanek, Lars Alexander Schneider, Nicolai Treiber, M. Huber, Dirk Debus, and Erwin S. Schultz
- Subjects
0301 basic medicine ,medicine.medical_specialty ,business.industry ,Melanoma ,Dermatology ,medicine.disease ,03 medical and health sciences ,030104 developmental biology ,0302 clinical medicine ,030220 oncology & carcinogenesis ,medicine ,Vemurafenib ,business ,medicine.drug - Published
- 2017
23. Impact of radiation, systemic therapy and Treatment sequencing on survival of patients with melanoma brain metastases
- Author
-
Johannes Bruns, Esther G.C. Troost, Felix Kiecker, Julia Brütting, Andrea Forschner, Jennifer Linn, Ralf Gutzmer, Katharina C. Kaehler, Jessica C. Hassel, David Rafei-Shamsabadi, Andreas Arnold, Jochen Utikal, Marlene Garzarolli, Lisa Zimmer, Patrik Terheyden, Frank Meiss, Friedegund Meier, Evelyn Dabrowski, Daniel Zips, Steffen Löck, Stefan Beissert, Carola Berking, Fabian Lohaus, Marvin Kuske, Dirk Debus, Dirk Daubner, and Ricarda Rauschenberg
- Subjects
0301 basic medicine ,Oncology ,Male ,Cancer Research ,Skin Neoplasms ,medicine.medical_treatment ,Medizin ,Systemic therapy ,Targeted therapy ,0302 clinical medicine ,Germany ,Molecular Targeted Therapy ,Melanoma ,Aged, 80 and over ,Brain Neoplasms ,BRAF inhibitors ,Middle Aged ,Combined Modality Therapy ,Survival Rate ,Treatment Outcome ,030220 oncology & carcinogenesis ,Female ,Immunotherapy ,Whole brain radiation therapy ,Adult ,Proto-Oncogene Proteins B-raf ,medicine.medical_specialty ,Radiosurgery ,03 medical and health sciences ,Whole brain Radiation therapy ,Immune checkpoint inhibitors ,Internal medicine ,medicine ,Humans ,In patient ,Stereotactic radiosurgery ,Aged ,Retrospective Studies ,business.industry ,Brain metastases ,medicine.disease ,Radiation therapy ,030104 developmental biology ,Mutation ,business ,Immunotherapies - Abstract
Background Combining stereotactic radiosurgery (SRS) and active systemic therapies (STs) achieved favourable survival outcomes in patients with melanoma brain metastases (MBMs) in retrospective analyses. However, several aspects of this Treatment strategy remain poorly understood. We Report on the Overall survival (OS) of patients with MBM treated with a combination of radiotherapy (RT) and ST as well as the Impact of the v-Raf murine sarcoma viral oncogene homolog B (BRAF)-V600 Mutation (BRAFmut) status, types of RT and ST and their sequence. Patients and methods Data of 208 patients treated with SRS or whole brain Radiation therapy (WBRT) and either immunotherapy (IT) or targeted therapy (TT) within a 6-week- interval to RT were analysed retrospectively. OS was calculated from RT to death or last follow-up. Univariate- and multivariate Cox proportional hazard analyses were performed to determine prognostic Features associated with OS. Results The median follow-up was 7.3 months. 139 patients received IT, 67 received TT and 2 received IT and TT within 6 weeks to RT (WBRT 45%; SRS 55%). One-year Kaplan-Meier OS rates were 69%, 65%, 33% and 18% (P < .001) for SRS with IT, SRS with TT, WBRT with IT and WBRT with TT, respectively. Patients with a BRAF mut receiving IT combined with RT experienced higher OS rates (88%, 65%, 50% and 18%). TT following RT or started before and continued thereafter was associated with improved median OS compared with to TT solely before RT (12.2 [95% confidence interval {CI} 9.3–15.1]; 9.8 [95% CI 6.9–12.6] versus 5.1 [95% CI 2.7–7.5]; P = .03). Conclusion SRS and IT achieved the highest OS rates. A BRAFmut appears to be a favourable prognostic factor for OS. For the combination of RT and TT, the sequence appears to be crucial. Combinations of WBRT and ST achieved unprecedentedly high OS rates and Warrant further studies.
- Published
- 2019
24. Afatinib-associated Stevens-Johnson syndrome in an EGFR-mutated lung cancer patient
- Author
-
Wolfgang M. Brueckl, Dirk Debus, Joachim H. Ficker, Janine Doesch, Erwin S. Schultz, Christian Meyer, and Thomas Papadopoulos
- Subjects
0301 basic medicine ,Pulmonary and Respiratory Medicine ,Oncology ,Cancer Research ,medicine.medical_specialty ,Lung Neoplasms ,medicine.drug_class ,Afatinib ,Tyrosine-kinase inhibitor ,03 medical and health sciences ,0302 clinical medicine ,Adrenal Cortex Hormones ,Internal medicine ,medicine ,Humans ,Epidermal growth factor receptor ,Lung cancer ,Adverse effect ,Protein Kinase Inhibitors ,Aged ,Skin ,biology ,business.industry ,Stevens johnson ,medicine.disease ,respiratory tract diseases ,Discontinuation ,ErbB Receptors ,stomatognathic diseases ,Treatment Outcome ,030104 developmental biology ,Stevens-Johnson Syndrome ,030220 oncology & carcinogenesis ,Mutation ,Quinazolines ,biology.protein ,Female ,business ,Glucocorticoid ,medicine.drug - Abstract
Introduction Afatinib is a tyrosine kinase inhibitor (TKI), that has been approved for treating patients with epidermal growth factor receptor (EGFR) mutated advanced non-small-cell lung cancer (NSCLC). Stevens-Johnson syndrome (SJS) related to EGFR directed TKIs is a rare adverse event. Case presentation We report a case of a 79-year-old white female with EGFR-mutated, metastatic non-small-cell lung cancer treated with afatinib as first-line palliative treatment, who developed a SJS after two months of treatment. Discontinuation of the TKI and systemic glucocorticoid treatment led to improvement of symptoms and recovery. Conclusion Severe adverse cutaneous drug reactions that predominantly involve the skin and mucous membranes during treatment with afatinib should alert clinicians to suspect SJS and react appropriately.
- Published
- 2016
25. A prospective observational safety study of patients with <scp> BRAF V </scp> 600 ‐mutated unresectable or metastatic melanoma treated with vemurafenib (Zelboraf Safety Study)
- Author
-
M. Blasinska‐Morawiec, J.J. Hsu, K. Freivogel, Grant R. Goodman, Piotr Rutkowski, Dawn Colburn, Natalia Sadetsky, R. Jansen, Rudolf A. Herbst, Maria Marples, R. Marconcini, M.L.G. Munson, Dirk Debus, Patrick Terheyden, A.J. ten Tije, and Pippa Corrie
- Subjects
Oncology ,medicine.medical_specialty ,Metastatic melanoma ,business.industry ,Internal medicine ,Medicine ,Observational study ,Dermatology ,business ,Vemurafenib ,medicine.drug - Published
- 2019
26. Intervalltherapie mit Vemurafenib beim malignen Melanom
- Author
-
Nicolai, Treiber, Margit Anna, Huber, Lars Alexander, Schneider, Karin, Scharffetter-Kochanek, Erwin, Schultz, and Dirk, Debus
- Published
- 2017
27. Intermittent vemurafenib therapy in malignant melanoma
- Author
-
Nicolai, Treiber, Margit Anna, Huber, Lars Alexander, Schneider, Karin, Scharffetter-Kochanek, Erwin, Schultz, and Dirk, Debus
- Subjects
Skin Neoplasms ,Vemurafenib ,Humans ,Antineoplastic Agents ,Melanoma - Published
- 2017
28. Actual practice of melanoma follow-up and treatment in Germany: results of a prospective, longitudinal cohort study
- Author
-
Dorothee Nashan, A. Mauerer, Dirk Schadendorf, Uwe Trefzer, Christine Windemuth-Kieselbach, Edgar Dippel, Thomas Eigentler, Dirk Debus, Elisabeth Livingstone, Rainer Rompel, K. Möllenhoff, Katharina C. Kähler, Katharina Kilian, and Axel Hauschild
- Subjects
Male ,Pediatrics ,medicine.medical_specialty ,Skin Neoplasms ,business.industry ,Medizin ,Retrospective cohort study ,Dermatology ,Middle Aged ,Neoadjuvant Therapy ,Germany ,Actual practice ,Disease Progression ,Medicine ,Humans ,Female ,Prospective Studies ,Longitudinal cohort ,business ,Prospective cohort study ,Melanoma ,Cohort study ,Follow-Up Studies ,Neoplasm Staging - Published
- 2014
29. Fortgeschrittenes Melanom: Checkpointinhibitoren im Vergleich
- Author
-
Judith Neumaier and Dirk Debus
- Subjects
Gynecology ,medicine.medical_specialty ,Surgical oncology ,business.industry ,medicine ,business - Abstract
In der Phase-III-Studie KEYNOTE-006 wurde Pembrolizumab mit Ipilimumab, der bisherigen Standardtherapie bei fortgeschrittenem Melanom, verglichen.
- Published
- 2015
30. Rituximab Exerts a Dual Effect in Pemphigus Vulgaris
- Author
-
Eva Podstawa, Rüdiger Eming, Sonja Wolff-Franke, Michael Hertl, Dirk Debus, and Angela Nagel
- Subjects
medicine.medical_specialty ,biology ,business.industry ,Cell adhesion molecule ,CD3 ,Pemphigus vulgaris ,Cell Biology ,Dermatology ,medicine.disease ,Biochemistry ,Desmoglein ,Endocrinology ,Downregulation and upregulation ,Internal medicine ,Monoclonal ,Immunology ,biology.protein ,Medicine ,Rituximab ,Antibody ,business ,Molecular Biology ,medicine.drug - Abstract
Pemphigus vulgaris (PV) is a severe autoimmune blistering disease affecting the skin and mucous membranes. Autoreactive CD4(+) T helper (Th) lymphocytes are crucial for the autoantibody response against the desmosomal adhesion molecules, desmoglein (dsg)-3 and dsg1. Eleven patients with extensive PV were treated with the anti-CD20 antibody, rituximab (375 mg per m(2) body surface area once weekly for 4 weeks). Frequencies of autoreactive CD4(+) Th cells in the peripheral blood of the PV patients were determined 0, 1, 3, 6, and 12 months after rituximab treatment. Additionally, the clinical response was evaluated and serum autoantibody titers were quantified by ELISA. Rituximab induced peripheral B-cell depletion for 6-12 months, leading to a dramatic decline of serum autoantibodies and significant clinical improvement in all PV patients. The frequencies of dsg3-specific CD4(+) Th1 and Th2 cells decreased significantly for 6 and 12 months, respectively, while the overall count of CD3(+)CD4(+) T lymphocytes and the frequency of tetanus toxoid-reactive CD4(+) Th cells remained unaffected. Our findings indicate that the response to rituximab in PV involves two mechanisms: (1) the depletion of autoreactive B cells and (2) the herein demonstrated, presumably specific downregulation of dsg3-specific CD4(+) Th cells.
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.